Ahn, E., Rothe, M., Mangat, P. K., Garrett-Mayer, E., Al Baghdadi, T., Baron, A. D., … Schilsky, R. L. (2022). 98P Olaparib (O) in patients (pts) with solid tumors with BRCA1/2 mutation (mut): Results from the targeted agent and profiling utilization registry (TAPUR) study. In Annals of Oncology (Vol. 33, pp. S583–S584). Elsevier BV. https://doi.org/10.1016/j.annonc.2022.07.130

Ahn, E., M. Rothe, P. K. Mangat, E. Garrett-Mayer, T. Al Baghdadi, A. D. Baron, J. C. Krauss, et al. “98P Olaparib (O) in patients (pts) with solid tumors with BRCA1/2 mutation (mut): Results from the targeted agent and profiling utilization registry (TAPUR) study.” In Annals of Oncology, 33:S583–84. Elsevier BV, 2022. https://doi.org/10.1016/j.annonc.2022.07.130.

Ahn E, Rothe M, Mangat PK, Garrett-Mayer E, Al Baghdadi T, Baron AD, et al. 98P Olaparib (O) in patients (pts) with solid tumors with BRCA1/2 mutation (mut): Results from the targeted agent and profiling utilization registry (TAPUR) study. In: Annals of Oncology. Elsevier BV; 2022. p. S583–4.

Ahn, E., et al. “98P Olaparib (O) in patients (pts) with solid tumors with BRCA1/2 mutation (mut): Results from the targeted agent and profiling utilization registry (TAPUR) study.” Annals of Oncology, vol. 33, Elsevier BV, 2022, pp. S583–84. Crossref, doi:10.1016/j.annonc.2022.07.130.

Ahn E, Rothe M, Mangat PK, Garrett-Mayer E, Al Baghdadi T, Baron AD, Krauss JC, Balmanoukian AS, Bauman JR, Hameed MK, Mileham KF, Thota R, Gold PJ, Meric-Bernstam F, Powell SF, Yang ES, O’Lone R, Grantham GN, Halabi S, Schilsky RL. 98P Olaparib (O) in patients (pts) with solid tumors with BRCA1/2 mutation (mut): Results from the targeted agent and profiling utilization registry (TAPUR) study. Annals of Oncology. Elsevier BV; 2022. p. S583–S584.